Blood transfusion · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in number of participants requiring blood transfusion compared with sucralfate (low certainty).
1 finding from 1 review
Serious adverse events · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically important upper GI bleeding · people admitted to intensive care units
H2 receptor antagonists probably leads to lower clinically important upper GI bleeding compared with placebo or no prophylaxis (moderate certainty).
1 finding from 1 review
Nosocomial pneumonia · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in nosocomial pneumonia compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
Meters change from baseline in 6MWD · pulmonary arterial hypertension
1 finding from 1 review
Proportion of participants with improved functional class mean duration of study 16.8 weeks · pulmonary arterial hypertension
Endothelin receptor antagonists probably leads to higher proportion of participants with improved functional class mean… compared with placebo (moderate certainty).
1 finding from 1 review
Change from baseline in BDI mean duration of study 14.3 weeks · pulmonary arterial hypertension
1 finding from 1 review
Mortality mean duration of study 30.2 weeks · pulmonary arterial hypertension
Endothelin receptor antagonists showed no clear difference in mortality mean duration of study 30.2 weeks compared with placebo (low certainty).
1 finding from 1 review
Change from baseline in mean PAP (mmHg) mean duration of study 17.1 weeks · pulmonary arterial hypertension
1 finding from 1 review
Change from baseline in PVR (dyn/s/cm5) mean duration of study 15.7 weeks · pulmonary arterial hypertension
1 finding from 1 review
Hepatic toxicity mean duration of study 25 weeks · pulmonary arterial hypertension
Endothelin receptor antagonists showed no clear difference in hepatic toxicity mean duration of study 25 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life (MLHFQ): from 0 to 105 · patients with chronic heart failure with preserved ejection fraction
1 finding from 1 review
Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Mineralocorticoid receptor antagonists (MRAs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · patients with chronic heart failure with preserved ejection fraction
Mineralocorticoid receptor antagonists (MRAs) probably leads to lower heart failure hospitalisation (RR) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Hyperkalaemia · patients with chronic heart failure with preserved ejection fraction
Mineralocorticoid receptor antagonists (MRAs) leads to higher hyperkalaemia compared with placebo or no treatment (high certainty).
1 finding from 1 review
All‐cause mortality · patients with chronic heart failure with preserved ejection fraction
Mineralocorticoid receptor antagonists (MRAs) showed no clear difference in all‐cause mortality compared with placebo or no treatment (moderate certainty).
1 finding from 1 review